Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2026 16:01 ET | Source: Aura Biosciences, Inc.

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ...
May 11, 2026 16:01 ET | Source: Aura Biosciences, Inc.

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors ...
May 05, 2026 17:15 ET | Source: Aura Biosciences, Inc.

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve...
May 04, 2026 09:03 ET | Source: Aura Biosciences, Inc.

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve...
May 04, 2026 06:03 ET | Source: Aura Biosciences, Inc.

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve...
May 04, 2026 06:01 ET | Source: Aura Biosciences, Inc.

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of...
March 30, 2026 07:00 ET | Source: Aura Biosciences, Inc.

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 ...
February 25, 2026 07:00 ET | Source: Aura Biosciences, Inc.

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ...
November 24, 2025 16:05 ET | Source: Aura Biosciences, Inc.

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ...
November 13, 2025 07:00 ET | Source: Aura Biosciences, Inc.

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential...